Y. Rouscoff
University of Nice Sophia Antipolis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Y. Rouscoff.
Progres En Urologie | 2014
J.-W. Lee; D. Chevallier; J. Gal; Y. Rouscoff; R. Natale; Marie-Eve Chand; C. Raffaelli; D. Ambrosetti; M. Durand; Jean Amiel; Jean-Michel Hannoun-Levi
OBJECTIVES To evaluate the toxicity of therapeutic sequences High Intensity Focused Ultrasound (HIFU)-salvage radiotherapy (HIFU-RT) or radiotherapy-salvage HIFU (RT-HIFU) in case of locally recurrent prostate cancer. MATERIALS AND METHODS Nineteen patients had a local recurrence of prostate cancer. Among them, 10 patients were treated by HIFU-RT and 9 patients by RT- HIFU (4 by external beam radiotherapy [EBR] and 5 by brachytherapy [BRACHY]). Urinary side effects were assessed using CTCAE v4. RESULTS At the time of the initial management, the median age was 66.5 years (53-72), the median PSA was 10.8ng/mL (3.4-50) and the median initial Gleason score was 6.3 (5-8). Median follow-up after salvage treatment was 46.3 months (2-108). Thirty percent of the patients in the HIFU-RT group and 33.3 % of the patients in the RT-HIFU group, all belonging to the sub-group BRACHY-HIFU, had urinary complication greater than or equal to grade 2. Among all the patients, only 1 had grade 1 gastrointestinal toxicity. CONCLUSION BRACHY-HIFU sequence seems to be purveyor of many significant urinary side effects. A larger database is needed to confirm this conclusion.
Progres En Urologie | 2014
M. El Mrini; N. Abakka; Y. Rouscoff; N. Barry Delongchamps; D. Saighi; M. Peyromaure; M. Zerbib; Evanguelos Xylinas
des greffons était diminué à 1 h et à 3mois après la transplantation. Dans le cortex total des greffons, il a été mis en évidence une augmentation du nombre de bifurcations des segments vasculaires et le développement d’un tissu fibreux qui participe au remodelage vasculaire (Fig. 1d). Conclusion Ce travail apporte des indications sur le spectre lésionnel de l’ischémie reperfusion rénale et permettra de développer des futures thérapies dans le but d’améliorer la préservation du réseau microvasculaire du greffon rénal.
Radiation Oncology | 2014
Y. Rouscoff; Alexander Tuan Falk; M. Durand; Jocelyn Gal; Marie-Eve Chand; Mathieu Gautier; Alexandre Marsaud; D. Chevallier; Jean Amiel; Jean-Michel Hannoun-Levi
The Journal of Urology | 2015
Y. Rouscoff; Yohan Dabi; Nicolas Barry Delongchamps; Djillali Saighi; Marc Zerbib; Michaël Peyromaure; Evanguelos Xylinas
Progres En Urologie | 2015
B. Tibi; E. Vincens; M. Durand; D. Salet-Lizet; P. Gadonneix; A. Kane; X. Carpentier; A. Marsaud; Y. Rouscoff; D. Chevallier; Jean Amiel; R. Villet
The Journal of Urology | 2014
Alexandre Marsaud; Damien Ambrosetti; Matthieu Durand; Xavier Carpentier; Aurélie Floc'h; Y. Rouscoff; Brannwel Tibi; Florence Dupré; Emmanuel Chamorey; Daniel Chevallier; Jean Amiel; Jean François Michiels; Florence Pedeutour
The Journal of Urology | 2014
Brannwel Tibi; Matthieu Durand; Claire Mauduit; Xavier Carpentier; Y. Rouscoff; Ji wann Lee; Alexandre Marsaud; Damien Ambrosetti; Jean François Michiels; François Severac; Hervé Quintens; Zeinab Mahate; Victoria Wijeratne; Jean Amiel; Daniel Chevallier; Mohamed Benahmed
The Journal of Urology | 2014
Alexandre Marsaud; Charles Raffaelli; Matthieu Durand; Xavier Carpentier; Aurélie Floc'h; Y. Rouscoff; Brannwel Tibi; Eric Fontas; Jean Amiel; Daniel Chevallier
Progres En Urologie | 2014
M. Durand; F. Colomb; A. Marsaud; Y. Rouscoff; J. Lee; L. Mendel; X. Carpentier; R. Haider; D. Chevallier; M. Carles
Progres En Urologie | 2014
B. Tibi; M. Durand; Y. Rouscoff; J. Lee; C. Mauduit; D. Ambrosetti; Z. Mahate; V. Wijeratne; F. Severac; X. Carpentier; A. Marsaud; N. Mentine; H. Quintens; Jean Amiel; D. Chevallier; M. Benahmed